|
|
| | GSK-340 Basic information |
| Product Name: | GSK-340 | | Synonyms: | GSK-340;Ethanone, 1-[(2S)-2-cyclopropyl-3,4-dihydro-4-[[2-(hydroxymethyl)phenyl]methyl]-6-(1,2,3,6-tetrahydro-4-pyridinyl)-1(2H)-quinoxalinyl]- | | CAS: | 2222509-79-5 | | MF: | C26H31N3O2 | | MW: | 417.54 | | EINECS: | | | Product Categories: | | | Mol File: | 2222509-79-5.mol |  |
| | GSK-340 Chemical Properties |
| Boiling point | 695.5±55.0 °C(Predicted) | | density | 1.238±0.06 g/cm3(Predicted) | | pka | 14.25±0.10(Predicted) |
| | GSK-340 Usage And Synthesis |
| Uses | GSK-340 is a BET inhibitor with high affinity and significant selectivity for BD2 from BRD4 with a pIC50 of 7.2. GSK-340 inhibits MCP-1 release in Lipopolysaccharide (HY-D1056) treated PBMCs and whole blood with the pIC50 of 7.4 and 6.0, respectively. GSK-340 has immunomodulatory activity[1]. | | References | [1] Law RP, et al. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. J Med Chem. 2018 May 24;61(10):4317-4334. DOI:10.1021/acs.jmedchem.7b01666 |
| | GSK-340 Preparation Products And Raw materials |
|